Kura Interest Expense vs Cost Of Revenue Analysis

KURA Stock

USD 18.57 1.01 5.75%

Kura Oncology financial indicator trend analysis is infinitely more than just investigating Kura Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kura Oncology is a good investment. Please check the relationship between Kura Oncology Interest Expense and its Cost Of Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.

Interest Expense vs Cost Of Revenue

Interest Expense vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kura Oncology Interest Expense account and Cost Of Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Kura Oncology's Interest Expense and Cost Of Revenue is 0.62. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Kura Oncology, assuming nothing else is changed. The correlation between historical values of Kura Oncology's Interest Expense and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Kura Oncology are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Interest Expense i.e., Kura Oncology's Interest Expense and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Cost Of Revenue

Cost of Revenue is found on Kura Oncology income statement and represents the costs associated with goods and services Kura Oncology provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Kura Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 155.6 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (6.57).

Kura Oncology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Other Stockholder Equity	Total Current Assets	Common Stock	Short Long Term Debt Total	Total Current Liabilities	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Short Term Debt	Other Current Liab	Accounts Payable	Common Stock Total Equity	Other Current Assets	Net Tangible Assets	Retained Earnings Total Equity	Capital Surpluse	Non Current Assets Total	Non Currrent Assets Other	Other Liab
Total Assets		-0.27	-0.69	-0.85	0.73	1.0	0.4	1.0	-0.04	0.84	0.91	0.95	0.93	0.77	0.88	0.2	0.87	0.64	0.95	0.87	1.0	-0.9	0.95	0.88	0.7	-0.61
Total Stockholder Equity	-0.27		0.39	-0.05	-0.37	-0.29	0.73	-0.28	0.0	0.11	0.06	-0.21	-0.11	0.17	0.09	0.0	0.14	-0.27	-0.1	-0.22	-0.19	0.16	-0.08	0.11	0.34	0.06
Net Debt	-0.69	0.39		0.25	-1.0	-0.7	0.1	-0.7	0.01	-0.43	-0.42	-0.83	-0.39	-0.28	-0.38	-0.34	-0.33	-0.37	-0.46	-0.33	-0.66	0.34	-0.46	-0.38	-0.06	0.25
Retained Earnings	-0.85	-0.05	0.25		-0.32	-0.84	-0.72	-0.85	0.01	-0.88	-0.96	-0.74	-0.96	-0.9	-0.96	-0.01	-0.98	-0.47	-0.94	-0.94	-0.88	0.98	-0.97	-0.97	-0.95	0.56
Cash	0.73	-0.37	-1.0	-0.32		0.74	-0.04	0.74	-0.01	0.49	0.48	0.87	0.44	0.35	0.44	0.34	0.39	0.4	0.52	0.39	0.7	-0.39	0.52	0.44	0.13	-0.3
Cash And Short Term Investments	1.0	-0.29	-0.7	-0.84	0.74		0.38	1.0	-0.04	0.84	0.91	0.95	0.92	0.76	0.87	0.2	0.86	0.65	0.95	0.86	0.99	-0.89	0.94	0.87	0.69	-0.61
Other Stockholder Equity	0.4	0.73	0.1	-0.72	-0.04	0.38		0.39	-0.01	0.68	0.7	0.36	0.59	0.73	0.72	0.0	0.77	0.14	0.58	0.5	0.48	-0.56	0.62	0.74	0.89	-0.34
Total Current Assets	1.0	-0.28	-0.7	-0.85	0.74	1.0	0.39		-0.04	0.84	0.91	0.95	0.92	0.77	0.88	0.2	0.86	0.65	0.95	0.87	0.99	-0.9	0.95	0.88	0.69	-0.61
Common Stock	-0.04	0.0	0.01	0.01	-0.01	-0.04	-0.01	-0.04		-0.01	0.0	-0.02	-0.09	-0.01	0.0	0.02	-0.03	-0.09	-0.07	-0.03	-0.03	0.03	-0.03	0.0	-0.01	0.22
Short Long Term Debt Total	0.84	0.11	-0.43	-0.88	0.49	0.84	0.68	0.84	-0.01		0.94	0.82	0.88	0.94	0.96	0.34	0.93	0.59	0.92	0.86	0.86	-0.85	0.9	0.86	0.83	-0.78
Total Current Liabilities	0.91	0.06	-0.42	-0.96	0.48	0.91	0.7	0.91	0.0	0.94		0.85	0.97	0.93	0.99	0.1	0.99	0.62	0.98	0.9	0.94	-0.94	0.98	0.95	0.91	-0.66
Other Assets	0.95	-0.21	-0.83	-0.74	0.87	0.95	0.36	0.95	-0.02	0.82	0.85		0.82	0.74	0.83	0.26	0.79	0.55	0.86	0.75	0.95	-0.77	0.86	0.8	0.59	-0.53
Common Stock Shares Outstanding	0.93	-0.11	-0.39	-0.96	0.44	0.92	0.59	0.92	-0.09	0.88	0.97	0.82		0.89	0.96	0.06	0.96	0.65	0.99	0.94	0.94	-0.98	0.98	0.93	0.88	-0.67
Non Current Liabilities Total	0.77	0.17	-0.28	-0.9	0.35	0.76	0.73	0.77	-0.01	0.94	0.93	0.74	0.89		0.97	0.12	0.94	0.55	0.89	0.85	0.8	-0.86	0.87	0.85	0.89	-0.67
Total Liab	0.88	0.09	-0.38	-0.96	0.44	0.87	0.72	0.88	0.0	0.96	0.99	0.83	0.96	0.97		0.11	0.99	0.6	0.97	0.9	0.91	-0.93	0.96	0.94	0.92	-0.67
Short Term Debt	0.2	0.0	-0.34	-0.01	0.34	0.2	0.0	0.2	0.02	0.34	0.1	0.26	0.06	0.12	0.11		0.06	0.17	0.12	0.07	0.18	-0.04	0.1	0.08	-0.02	-0.57
Other Current Liab	0.87	0.14	-0.33	-0.98	0.39	0.86	0.77	0.86	-0.03	0.93	0.99	0.79	0.96	0.94	0.99	0.06		0.55	0.96	0.9	0.9	-0.94	0.97	0.97	0.95	-0.62
Accounts Payable	0.64	-0.27	-0.37	-0.47	0.4	0.65	0.14	0.65	-0.09	0.59	0.62	0.55	0.65	0.55	0.6	0.17	0.55		0.69	0.5	0.62	-0.53	0.56	0.42	0.42	-0.78
Common Stock Total Equity	0.95	-0.1	-0.46	-0.94	0.52	0.95	0.58	0.95	-0.07	0.92	0.98	0.86	0.99	0.89	0.97	0.12	0.96	0.69		0.92	0.96	-0.96	0.98	0.92	0.86	-0.71
Other Current Assets	0.87	-0.22	-0.33	-0.94	0.39	0.86	0.5	0.87	-0.03	0.86	0.9	0.75	0.94	0.85	0.9	0.07	0.9	0.5	0.92		0.88	-0.98	0.94	0.87	0.8	-0.61
Net Tangible Assets	1.0	-0.19	-0.66	-0.88	0.7	0.99	0.48	0.99	-0.03	0.86	0.94	0.95	0.94	0.8	0.91	0.18	0.9	0.62	0.96	0.88		-0.91	0.97	0.92	0.76	-0.6
Retained Earnings Total Equity	-0.9	0.16	0.34	0.98	-0.39	-0.89	-0.56	-0.9	0.03	-0.85	-0.94	-0.77	-0.98	-0.86	-0.93	-0.04	-0.94	-0.53	-0.96	-0.98	-0.91		-0.98	-0.93	-0.86	0.6
Capital Surpluse	0.95	-0.08	-0.46	-0.97	0.52	0.94	0.62	0.95	-0.03	0.9	0.98	0.86	0.98	0.87	0.96	0.1	0.97	0.56	0.98	0.94	0.97	-0.98		0.97	0.88	-0.6
Non Current Assets Total	0.88	0.11	-0.38	-0.97	0.44	0.87	0.74	0.88	0.0	0.86	0.95	0.8	0.93	0.85	0.94	0.08	0.97	0.42	0.92	0.87	0.92	-0.93	0.97		0.92	-0.5
Non Currrent Assets Other	0.7	0.34	-0.06	-0.95	0.13	0.69	0.89	0.69	-0.01	0.83	0.91	0.59	0.88	0.89	0.92	-0.02	0.95	0.42	0.86	0.8	0.76	-0.86	0.88	0.92		-0.53
Other Liab	-0.61	0.06	0.25	0.56	-0.3	-0.61	-0.34	-0.61	0.22	-0.78	-0.66	-0.53	-0.67	-0.67	-0.67	-0.57	-0.62	-0.78	-0.71	-0.61	-0.6	0.6	-0.6	-0.5	-0.53

Click cells to compare fundamentals

Kura Oncology Account Relationship Matchups

Kura Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	242.0M	647.2M	534.1M	456.3M	448.9M	471.4M
Total Stockholder Equity	(212.9M)	(302.5M)	(433.0M)	(568.8M)	397.3M	417.1M
Net Debt	(18.6M)	(310.5M)	(83.8M)	(37.8M)	(20.1M)	(21.1M)
Retained Earnings	(212.9M)	(302.5M)	(433.0M)	(568.8M)	(721.4M)	(685.4M)
Cash	26.1M	325.5M	90.7M	51.8M	37.3M	40.2M
Cash And Short Term Investments	236.9M	633.3M	518.0M	438.0M	424.0M	445.2M
Liabilities And Stockholders Equity	(189.7M)	(266.2M)	(405.5M)	(532.8M)	448.9M	471.4M
Other Stockholder Equity	(336K)	(53K)	1.8M	8.0M	1.1B	1.2B
Total Current Assets	239.6M	637.3M	522.3M	446.4M	432.5M	454.1M
Common Stock	3K	4K	5K	7K	8.1K	6.7K
Total Current Liabilities	15.6M	26.0M	22.5M	24.1M	35.3M	37.0M
Other Assets	2.1M	7.9M	3.5M	3.5M	4.0M	4.2M
Common Stock Shares Outstanding	41.9M	53.1M	66.4M	67.0M	73.2M	76.9M
Non Current Liabilities Total	7.6M	10.3M	5.0M	12.0M	16.4M	17.2M
Total Liab	23.2M	36.3M	27.4M	36.0M	51.7M	54.2M
Other Current Liab	11.8M	18.2M	17.0M	20.2M	31.5M	33.0M
Accounts Payable	3.5M	2.8M	3.2M	1.5M	2.3M	1.9M
Common Stock Total Equity	3K	4K	5K	7K	8.1K	8.5K
Other Current Assets	2.7M	4.0M	4.3M	8.4M	5.7M	6.0M
Net Tangible Assets	218.8M	610.9M	506.6M	420.3M	483.3M	507.5M
Retained Earnings Total Equity	(212.9M)	(302.5M)	(433.0M)	(568.8M)	(511.9M)	(486.3M)
Capital Surpluse	431.3M	913.4M	941.4M	997.1M	1.1B	1.2B
Non Current Assets Total	2.4M	9.9M	11.8M	9.9M	16.5M	17.3M
Non Currrent Assets Other	2.3M	1.4M	3.3M	3.3M	7.4M	7.8M
Other Liab	377K	395K	375K	265K	238.5K	324.6K
Long Term Debt	7.5M	7.3M	4.3M	9.2M	9.3M	7.1M
Short Term Investments	210.8M	307.8M	427.3M	386.2M	386.6M	237.8M
Accumulated Other Comprehensive Income	331K	46K	(1.8M)	(8.0M)	(1.3M)	(1.3M)
Non Current Liabilities Other	377K	6.0M	5.0M	265K	705K	669.8K
Long Term Debt Total	7.5M	7.3M	4.3M	9.2M	10.5M	7.5M
Net Invested Capital	226.3M	618.2M	506.6M	429.4M	406.6M	383.8M
Net Working Capital	224.0M	611.3M	499.8M	422.4M	397.2M	378.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:

How To Invest In Kura

Details

Is Kura Stock a good investment?

Details

What is Kura Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.35)

Return On Assets

(0.29)

Return On Equity

(0.46)

The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kura Interest Expense vs Cost Of Revenue Analysis

Interest Expense vs Cost Of Revenue

Interest Expense vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Interest Expense

Cost Of Revenue

Kura Oncology fundamental ratios Correlations

Kura Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kura Oncology fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Tangible Assets	+ 0.99	Cash And Short Term Investments
Net Tangible Assets	+ 0.99	Total Current Assets

Cash	- 1.0	Net Debt
Capital Surpluse	- 0.98	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.98	Other Current Assets
Retained Earnings Total Equity	- 0.98	Common Stock Shares Outstanding
Other Current Liab	- 0.98	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings